Halberd Update on WatchDawg® PTSD Treatment
December 02, 2024 08:00 ET
|
Halberd Corp.
Halberd Update on WatchDawg® PTSD Treatment
Halberd & Athena GTX Report Initial Success of WatchDawg® PTSD Treatment Pilot Study
October 01, 2024 08:00 ET
|
Halberd Corp.
Halberd & Athena GTX Report Initial Success of WatchDawg® PTSD Treatment Pilot Study
Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD
September 11, 2024 08:00 ET
|
Halberd Corp.
Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD
Halberd Corp. Issues Letter to Shareholders - Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction
September 09, 2024 09:31 ET
|
Halberd Corp.
Halberd Corp. Issues Letter to Shareholders - Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction
Halberd Corp. Issues Letter to Shareholders - Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction
September 04, 2024 08:00 ET
|
Halberd Corp.
Halberd Corp. Issues Letter to Shareholders - Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction
Halberd Corp. Issues Letter to Shareholders
August 26, 2024 08:00 ET
|
Halberd Corp.
Halberd Corp. - Taking a Moment to Recenter Our Technical Progress
Halberd Corp’s (OTC: HALB) Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results
July 24, 2024 08:00 ET
|
Halberd Corp.
Halberd Corp’s (OTC: HALB) Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results